MindWalk Holdings Corp. Earnings Recaps
Q1 2027
Sep 19, 2026
MindWalk’s stock fell 11.5% after earnings, as investors appeared disappointed by the absence of disclosed ReefIQ contracts or values and the company’s larger loss despite 21% revenue growth. The quarter showed improved gross margin, but the outlook remains dependent on converting early enterprise discussions into recurring revenue.
Key takeaways
- Q1 fiscal 2027 revenue increased 21% year over year to CAD 3.8 million, up from CAD 3.2 million; management cited five consecutive quarters of year-over-year growth.
- Gross margin expanded to 59% from 48%, with gross profit rising to CAD 2.2 million from CAD 1.5 million.
- The company reported a larger loss, driven partly by a CAD 1.9 million increase in sales and marketing spending to support ReefIQ commercialization.
- MindWalk is in discussions with multiple large pharmaceutical companies regarding ReefIQ enterprise deployments, but provided no partner names or contract values, and the maturity of opportunities varies.
- Roughly 80% of the current commercial funnel by value is structured around broader platform partnerships and asset economics; the company also secured a CAD 30 million unsecured revolving facility at a fixed 7% interest rate.
Q3 2026
Mar 12, 2026
MindWalk Holdings Corp. achieved its third consecutive quarter of year-over-year revenue growth, reporting a 52% increase, while solidifying its market position with a groundbreaking one-year enterprise Lens AI platform contract.
Key takeaways
- Revenue for Q3 fiscal year 2026 reached $4.2 million, reflecting a 52% increase from the previous year, driven primarily by growth in the U.S. market.
- The company's largest enterprise client signed a one-year contract for the Lens AI platform, transitioning to a recurring revenue model that enhances predictability and reduces the need for continuous reselling.
- Significant advancements in pipeline programs for dengue and influenza are ongoing, with promising data readouts expected soon, showcasing the unique capabilities of MindWalk's HIFT technology.
- The dengue program aims to address a major global health concern by focusing on balanced immunity across multiple serotypes, advancing to neutralization tests following successful immunization studies.